BRIEF published on 12/16/2025 at 09:58, 2 months 20 days ago Virbac acquires Thyronorm for the treatment of feline hyperthyroidism Acquisition Animal Health Feline Hyperthyroidism VIRBAC Thyronorm
BRIEF published on 12/16/2025 at 09:58, 2 months 20 days ago Virbac Acquires Thyronorm to Combat Feline Hyperthyroidism Veterinary Medicine Animal Health Feline Hyperthyroidism VIRBAC Thyronorm
PRESS RELEASE published on 12/16/2025 at 09:53, 2 months 20 days ago VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm Virbac acquires innovative drug Thyronorm from Norbrook to stabilize feline hyperthyroidism, expanding distribution in key markets and enhancing senior cats' quality of life Acquisition Feline Hyperthyroidism VIRBAC Thyronorm Senior Cats
BRIEF published on 11/07/2025 at 15:44, 3 months 27 days ago Virbac: Update on shares and voting rights Euronext Paris Voting Rights Actions Transparency VIRBAC
BRIEF published on 09/12/2025 at 17:50, 5 months 22 days ago Virbac Reports Solid Growth in 2025 First Half Results Revenue Growth Operating Income VIRBAC 2025 Forecast Global Market Performance
PRESS RELEASE published on 09/12/2025 at 17:45, 5 months 22 days ago Virbac: 2025 Half-year results Virbac reports solid revenue growth of 5.6% in the first half of 2025, meeting adjusted operating income expectations. Targets for 2025 confirmed with revenue growth of 4-6% expected Financial Results Revenue Growth Operating Income VIRBAC Targets Confirmed
BRIEF published on 08/18/2025 at 09:35, 6 months 18 days ago Virbac reveals the remuneration of its new CEO General Manager Remuneration VIRBAC Free Shares Paul Martingell
PRESS RELEASE published on 08/18/2025 at 09:30, 6 months 18 days ago Virbac:: Paul Martingell's compensation terms Virbac's board of directors approves compensation terms for Paul Martingell as CEO, including fixed and variable components, long-term incentives, and exceptional benefits Board Of Directors CEO VIRBAC Paul Martingell Compensation Terms
BRIEF published on 07/04/2025 at 12:09, 8 months 1 day ago Virbac: Status of Shares and Voting Rights as of June 30, 2025 Euronext Paris Voting Rights Actions 2025 VIRBAC
PRESS RELEASE published on 07/04/2025 at 12:04, 8 months 1 day ago Virbac : Declaration of the number of shares and voting rights 06/2025 Declaration of the number of shares and voting rights for VIRBAC on Euronext Paris. Total voting rights: 12,706,453. Net total voting rights: 12,693,617 Euronext Paris Voting Rights Shares Financial Market Authority VIRBAC
Published on 03/05/2026 at 14:00, 1 hour 37 minutes ago EQ Inc. Secures Strategic Partnership with Global Card Network to Expand Integrated Rewards Across Canada
Published on 03/05/2026 at 14:00, 1 hour 37 minutes ago GameSquare's Stream Hatchet Publishes 2025 YouTube Gaming Trends Report
Published on 03/05/2026 at 14:00, 1 hour 37 minutes ago Horizon Aircraft's Unique VTOL Delivers Up to 75% Lower Operating Costs Than Helicopters
Published on 03/05/2026 at 13:40, 1 hour 57 minutes ago Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Published on 03/05/2026 at 13:30, 2 hours 7 minutes ago Vox Royalty Provides 2026 Guidance and Increases Quarterly Dividend
Published on 03/05/2026 at 15:06, 31 minutes ago Form 8.3 - The Vanguard Group, Inc.: British Land Company plc, The
Published on 03/05/2026 at 15:05, 32 minutes ago Beyond Alliance: Leading Companies will direct $100m to Cut Superpollutants
Published on 03/04/2026 at 23:50, 15 hours 47 minutes ago Total number of voting rights and shares making up the share capital at February 28, 2026
Published on 03/04/2026 at 18:00, 21 hours 37 minutes ago Disclosure of Share Capital and Voting Rights as of February 28, 2026
Published on 03/04/2026 at 17:45, 21 hours 52 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
